Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a...

4

Transcript of Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a...

Page 1: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development
Page 2: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development
Page 3: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development
Page 4: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development

Biosimilars Clarified - Merck Clarifies Biosimilars · • Highlight Merck’s commitment to biosimilars. 3 Biological Productsand Biosimilars. 4 What Are Biological Products? MW,

Biosimilars Clarified - Merck Clarifies Biosimilars · • Highlight Merck’s commitment to biosimilars. 3 Biological Productsand Biosimilars. 4 What Are Biological Products? MW,

biocon stm

biocon stm

Dynamic Levels Biocon Ltd · The Biosimilars opportunity is set to expand as patents expire on leading biologics and patients demand lower priced drugs. ... Pharmaceutical Sector

Dynamic Levels Biocon Ltd · The Biosimilars opportunity is set to expand as patents expire on leading biologics and patients demand lower priced drugs. ... Pharmaceutical Sector

DIGITAL PROCESSING OF CD6 OUTPUT FOR DDO

DIGITAL PROCESSING OF CD6 OUTPUT FOR DDO

July 28 , 2017 Biocon Research Centre Kiran Mazumdar-Shaw Presentation_2017...drug market in 2022 projected to grow to US$ 337 billion Global biosimilars market in 2020 projected to

July 28 , 2017 Biocon Research Centre Kiran Mazumdar-Shaw Presentation_2017...drug market in 2022 projected to grow to US$ 337 billion Global biosimilars market in 2020 projected to

Anonymous - Wicca Beliefs and Practices Cd6 Id54201177 Size303

Anonymous - Wicca Beliefs and Practices Cd6 Id54201177 Size303

INVESTOR PRESENTATION - Biocon · Aim to address a Market Opportunity of US$ 0.8 Bn China Opportunity Biologics Biosimilars & Novel Biologics 13 NOVEL ... Biocon Biologics Global

INVESTOR PRESENTATION - Biocon · Aim to address a Market Opportunity of US$ 0.8 Bn China Opportunity Biologics Biosimilars & Novel Biologics 13 NOVEL ... Biocon Biologics Global

Sandozand Biocon strike global biosimilars alliance · 26January2018 Sandozand Biocon strike global biosimilars alliance COMPANYNEWS 2 Alkaloid to invest in two production sites 2

Sandozand Biocon strike global biosimilars alliance · 26January2018 Sandozand Biocon strike global biosimilars alliance COMPANYNEWS 2 Alkaloid to invest in two production sites 2

January 2011 - Biocon · Biosimilars partnership - Mylan Monoclonal Antibodies (MAb) Combines Biocon's R&D and manufacturing of novel biologics/bio-generics with Mylan’s regulatory

January 2011 - Biocon · Biosimilars partnership - Mylan Monoclonal Antibodies (MAb) Combines Biocon's R&D and manufacturing of novel biologics/bio-generics with Mylan’s regulatory

Biocon (BIOCON) Rs 567 - ICICI Directcontent.icicidirect.com/mailimages/Biocon -final.pdf · Biocon India incorporated as 70:30 JV between Indian promoters & Irish company Biocon

Biocon (BIOCON) Rs 567 - ICICI Directcontent.icicidirect.com/mailimages/Biocon -final.pdf · Biocon India incorporated as 70:30 JV between Indian promoters & Irish company Biocon

WHERE NEXT FOR BIOSIMILARS? - Insight, opinion and ... · PDF file01/14: Biocon confirms intention to launch CANMAb (biosimilar trastuzumab) in 150mg and 440mg presentations ... WHERE

WHERE NEXT FOR BIOSIMILARS? - Insight, opinion and ... · PDF file01/14: Biocon confirms intention to launch CANMAb (biosimilar trastuzumab) in 150mg and 440mg presentations ... WHERE

37th Annual General Meeting - Biocon · PDF file2019: US$24 billion (Estimated)^ Global Biosimilars Market^ Global Biosimilars in Clinical Development* ... different autoimmune diseases

37th Annual General Meeting - Biocon · PDF file2019: US$24 billion (Estimated)^ Global Biosimilars Market^ Global Biosimilars in Clinical Development* ... different autoimmune diseases

Shaping the biosimilars opportunity - Weinberg Group · PDF file2• SHAPING THE BIOSIMILARS OPPORTUNITY • December 2011 IMS HEALTH ... 2Pfizer to sell biosimilar insulins in Biocon

Shaping the biosimilars opportunity - Weinberg Group · PDF file2• SHAPING THE BIOSIMILARS OPPORTUNITY • December 2011 IMS HEALTH ... 2Pfizer to sell biosimilar insulins in Biocon

Biocon (Biocon) | 664content.icicidirect.com/mailimages/IDirect_Biocon_Q3FY19.pdf · Biocon was established in 1978 by first generation entrepreneur Dr Kiran Mazumdar-Shaw. Unlike

Biocon (Biocon) | 664content.icicidirect.com/mailimages/IDirect_Biocon_Q3FY19.pdf · Biocon was established in 1978 by first generation entrepreneur Dr Kiran Mazumdar-Shaw. Unlike

Biosimilar: Opportunity Thrusted over Indian ... · Alliance, Reliance Life Sciences, Biocon, Wockhardt, Intas are marketing biosimilars in India and other emerging markets. Intas

Biosimilar: Opportunity Thrusted over Indian ... · Alliance, Reliance Life Sciences, Biocon, Wockhardt, Intas are marketing biosimilars in India and other emerging markets. Intas

Exploracion y Produccion CD6

Exploracion y Produccion CD6

Flamion How are biosimilars assessedbiosimilarsconference.be/downs/presentations/2-ProfDrBFlamion_Howa... · Biocon/Mylan; BOW015® infliximab by Ranbaxy…) No or unclear regulation

Flamion How are biosimilars assessedbiosimilarsconference.be/downs/presentations/2-ProfDrBFlamion_Howa... · Biocon/Mylan; BOW015® infliximab by Ranbaxy…) No or unclear regulation

ANNUAL REPORT 2013 - Biocon · SBU: Biosimilars - Insulins & Monoclonal Antibodies The Next Wave of Growth Biosimilars are expected to provide the next wave of growth for Biocon as

ANNUAL REPORT 2013 - Biocon · SBU: Biosimilars - Insulins & Monoclonal Antibodies The Next Wave of Growth Biosimilars are expected to provide the next wave of growth for Biocon as

of the curve - Biocon · Global biosimilars market in 2020 projected to be between US$ 25 billion & US$ 35 billion@ Worldwide biotechnology drug market in 2022 projected to grow to

of the curve - Biocon · Global biosimilars market in 2020 projected to be between US$ 25 billion & US$ 35 billion@ Worldwide biotechnology drug market in 2022 projected to grow to

BIOCON- HRD

BIOCON- HRD